Sep 09, 2021 / 12:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Everybody, I'm Matthew Harrison, one of the Biotech analyst here at Morgan Stanley. Very pleased to have you join day 1 of our virtual conference and pleased to get started off with Genmab. And Jan van de Winkel, the CEO and President from Genmab. Just quickly before we start, I just need to read a disclosure statement.
Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. And with that, Jan, I'm going to turn it over to you to make a couple of minutes of opening remarks, and then we can jump into the Q&A.
Jan G.J. van de Winkel - Genmab A/S-Co-Founder - President & CEO
Thanks, Matthew. Good morning, everybody. We are delighted to be at this meeting. So Genmab had a very strong first half of the year and is on track, I think, for an excellent second half. We had,
Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers